Search Results - zhongyu+zhu

9 Results

Sort By:

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents

Abstract: The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology. The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Qi Zhao, Zhongyu Zhu

Keywords(s): Dimitrov, IGF-I, IGF-II, insulin-like growth factor, Monoclonal Antibody

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer

Abstract: The tumor microenvironment consists of a heterogenous population of cells which includes tumor cells and tumor-associated stroma cells (TASCs). The TASCs promote tumor angiogenesis, proliferation, invasion and metastasis. Because stroma cells are found in both healthy and cancerous tissue, targeting the tumor stroma has been difficult due...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire Ubani, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), ANTXR1, TEM8, Tumor Microenvironment, Tumor Stroma

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy

Abstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs,...

Published: 5/22/2024 | Inventor(s): Joost Oppenheim, Dimiter Dimitrov, De Yang, Xin Chen, Zhongyu Zhu

Keywords(s): ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage

Abstract: A child's growth is dependent on the proper functioning of the growth plate, a specialized cartilage structure located at the ends of long bones and within the vertebrae. The primary function of the growth plate is to generate new cartilage, which is then converted into bone tissue and results in the lengthening of bones. Failure of the growth...

Published: 4/8/2024 | Inventor(s): Jeffrey Baron, Sao Fong (Crystal) Cheung, Chun Lui, Dimiter Dimitrov, Zhongyu Zhu

Keywords(s): Anti-mantrilin-3 Antibody, ARTHRITIS, Baron, Cartilage, Dimitrov, Eunice Kennedy Shriver National Institute on Child Health an, Growth plate, Human Growth Hormone, monoclonal, NICHD, OSTEOARTHRITIS, Short Stature, Skeletal Dysplasia

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics

Abstract: Antibody drug conjugates (ADC) can demonstrate high efficacy as cancer therapeutics, however, much more can be done to improve their efficacy and safety profile. Site-specific antibody drug conjugation is a promising way to do this. Scientists at the NCI’s Laboratory of Experimental Immunology have identified a fully human monoclonal antibody,...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Pradman Qasba, Boopathy Ramakrishnan

Keywords(s): ADC, antibody drug conjugate, Dimitrov, HER2, Her2 positive, Her2-overexpression

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Therapeutic antibody-drug conjugates targeting CD56-positive cancers

Abstract: The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions. It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Yang Feng, Zhongyu Zhu, John Maris, Robyn Sussman

Keywords(s): ADC, GLYCOPROTEIN, MULTIPLE MYELOMA, Neuroblastoma, pyrrolobenzodiazepine, small-cell lung cancer

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Abstract: Targeting the CD22 receptor of B-cells with chimeric antigen receptor (CAR)-T cells has been a promising new therapy to treat B-cell malignancies in clinical trials, inducing remission in 70% of patients with relapsed acute lymphoblastic leukemia (ALL). However, diminished CD22 expression on B-cell surface can lead to relapse and decreased...

Published: 8/14/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Terry Fry, Sneha Ramakrishna

Keywords(s): Acute Lymphoblastic Leukemia, ALL, B Cell, CAR, CAR-T, CD22, chimeric antigen receptor, Dimitrov, T cell

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use

Abstract: Several Fibroblast Growth Factor Receptor 4 (FGFR4) specific antibodies with binding affinity at the nanomolar range have been successfully developed at the Genetics Branch. These antibodies have been made into different formats of therapeutic including Antibody Drug Conjugate (ADC), Bispecific T cell engager (BiTE) ae well as Chimeric Antigen...

Published: 4/8/2024 | Inventor(s): Javed Khan, Sivasubramanian Baskar, Dimiter Dimitrov, Zhongyu Zhu, Rimas Orentas, Adam Cheuk

Keywords(s): FGFR4, Fibroblast Growth Factor Receptor 4, Immunotherapy, Khan, Monoclonal Antibodies, Rhabdomyosarcoma, RMS

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology